Basilea has reported positive interim results from the derazantinib Phase II registration trial in intrahepatic cholangiocarcinoma (iCCA, bile duct cancer). The promising efficacy shown highlights the potential for the product in FGFR-driven solid tumours, an unmet need. Full data are expected to be available once the study has completed (mid-2020). Basilea in-licensed derazantinib from ArQule in April 2018. The asset is a complementary addition to its oncology portfolio and the company now h
10 Jan 2019
Basilea Pharmaceutica - Derazantinib interim iCCA data promising
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Basilea Pharmaceutica - Derazantinib interim iCCA data promising
Basilea Pharmaceutica AG (BSLN:SWX) | 0 0 0.0%
- Published:
10 Jan 2019 -
Author:
Dr Susie Jana -
Pages:
3
Basilea has reported positive interim results from the derazantinib Phase II registration trial in intrahepatic cholangiocarcinoma (iCCA, bile duct cancer). The promising efficacy shown highlights the potential for the product in FGFR-driven solid tumours, an unmet need. Full data are expected to be available once the study has completed (mid-2020). Basilea in-licensed derazantinib from ArQule in April 2018. The asset is a complementary addition to its oncology portfolio and the company now h